Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation values from 44,809 participants of the HEIRS Study

Andrew Lim MD1, Mark Speechley PhD2, Paul C Adams MD1


INTRODUCTION: The simultaneous interpretation of serum ferritin level and transferrin saturation has been used as a clinical guide to diagnose genetic hemochromatosis. The Hemochromatosis and Iron Overload Screening (HEIRS) Study screened 101,168 North American participants for serum ferritin level and transferrin saturation, and C282Y genotyping for the HFE gene.

METHODS: Logistic regression involving a subsample of Caucasians (n=44,809) was used to predict individual probabilities of HFE C282Y homozygosity using serum ferritin and transferrin saturation values. Men (n=17,323) and women (n=27,486) were analyzed separately. Regression equations were evaluated using area under the curve from ROC analysis and variance explained by Nagelkerke’s pseudo R-squared. An Android smartphone App and website application were developed to provide physicians with easy access to predicting C282Y homozygosity of the HFE gene.

RESULTS: The logistic equation had an area under the ROC curve of 0.91 for men and 0.89 for women. The pseudo R-squared was 0.44 for men and 0.34 for women. An example analysis was a Caucasian man with a transferrin saturation of 50% and a ferritin level of 500 µg/L, who had a 1.3% (95% CI 1.1% to 8.8%) probability of being a C282Y homozygote.

CONCLUSIONS: A large primary care-based sample of 44,809 participants contributed to the development of a new computer/smartphone tool that predicts the probability of being a C282Y homozygote of the HFE gene from serum ferritin and transferrin saturation values.

Key Words: Haemochromatosis; Hemochromatosis; Iron overload

Hemochromatosis is one of the most common genetic diseases in Caucasian populations; the typical genotype (C282Y mutation of the HFE gene) is observed in one in 227 Caucasians (1). In many affected patients, an elevation in both serum transferrin saturation and serum ferritin values is observed; however, the degree of elevation varies widely and there are nonexpressing C282Y homozygotes with normal serum ferritin levels and transferrin saturation. Many patients are overdiagnosed with hemochromatosis based on elevated values of these iron tests, and serum ferritin level is often elevated for other reasons such as inflammation, daily alcohol use and obesity (2). The simultaneous interpretation of serum ferritin and transferrin saturation values is a common clinical task in the approach to the diagnosis of hemochromatosis (3). In the present study, we developed logistic regression equations to predict the C282Y genotype from a large primary care-based population sample of Caucasian participants.

METHODS: The study design and overall results of the Hemochromatosis and Iron Overload Screening (HEIRS) Study have been previously reported (1,4). The HEIRS Study was approved by all local institutional review boards. Participants ≥25 years of age who gave informed consent were recruited from five field centres that, by design, served ethnically and socioeconomically diverse populations. All participants were screened for serum unsaturated iron-binding capacity, serum iron and serum ferritin levels (without intentional fasting), and genotyping to detect the common C282Y and H63D mutations of the HFE gene. Participants who, at recruitment, reported a previous diagnosis of hemochromatosis or iron overload (treated or untreated) were excluded. The present project used only participants self-identified as Caucasian because C282Y-linked hemochromatosis is extremely rare in non-Caucasians.

1Department of Medicine; 2Department of Epidemiology & Biostatistics and Schulich Interfaculty Program in Public Health, Western University, London, Ontario

Correspondence: Dr Paul C Adams, Department of Medicine, University Hospital, 339 Windermere Road, London, Ontario N6A 2E8.

Telephone 519-685-8500 ext 35375, fax 519-663-3549, e-mail padams@uwo.ca

Received for publication February 23, 2014. Accepted September 8, 2014

©2014 Pulsus Group Inc. All rights reserved

Can J Gastroenterol Hepatol Vol 28 No 9 October 2014
A Bernoulli regression model was fitted to the population-based HEIRS data. The regression model had the binary response variable C282Y homozygote (0,1), and continuous explanatory variables serum ferritin level and transferrin saturations (C282Y ~ transferrin saturation + ferritin). Analysis was performed using R Statistical Software. The amount of variance in the response variable explained by the model was estimated using Nagelkerke's pseudo R-squared statistic; the predictive accuracy was estimated using ROC curves. Two-dimensional plots were generated, one with a fixed transferrin saturation and increasing ferritin level, the other with a fixed ferritin level and increasing transferrin saturation.

A free Android smartphone application was developed to enable clinicians to input serum ferritin and transferrin saturation values to obtain the probability of the patient being a C282Y homozygote with a 95% CI. A website calculator was also developed (http://lim.bri-chacek.ca/services.html).

RESULTS

The Bernoulli regression equations are presented below (P = probability of being a C282Y homozygote, F = serum ferritin level, TS = transferrin saturation).

Men (n=17,323)

\[
P(F,TS) = \frac{100}{1+e^{-1(-9.6909061643+0.0009248193\cdot F+0.0976232890\cdot TS)}}
\]

Women (n=27,486)

\[
P(F,TS) = \frac{100}{1+e^{-1(-9.6909061643+0.0009248193\cdot F+0.0976232890\cdot TS)}}
\]

The ROC curves for the Bernoulli equations to predict C282Y homozygosity are shown in Figures 1 and 2. The probability of being a C282Y homozygote with an increasing serum ferritin level and transferrin saturation is shown in Figures 3 and 4.

DISCUSSION

The present study used a large primary care-based population study to create regression equations to predict the C282Y genotype of hemochromatosis. A novel aspect of the study was the development of predictive smartphone application and a web-based calculator.

Despite the large sample size and high area under the curve values, the individual predictive probabilities have wide CIs. This reflects both the relative paucity of C282Y homozygotes in the primary care-based sample and the number of conditions other than HFE mutations that affect transferrin and ferritin. Specifically, there are some C282Y homozygotes with normal transferrin saturation and ferritin levels, and many more participants with elevations in transferrin saturation and/or ferritin who do not have the C282Y genotype. With a high transferrin saturation and serum ferritin level, there are fewer non-C282Y homozygotes with this same pattern of tests; therefore, the probability is higher. At lower transferrin saturation and serum ferritin values, there are many more non-C282Y homozygotes in the population-based sample who may have elevated values secondary to inflammation, fatty liver, chronic alcohol ingestion and obesity.

These tools are for the prediction of the C282Y genotype, which is not synonymous with the prediction of iron overload. It is not possible to perform this analysis for iron overload because an independent measure of iron status is not available in the population sample. We have previously reported on the use of transferrin saturation values to predict hepatic iron overload in a significantly smaller sample (5). It also is unlikely that fasting blood samples would have improved the predictions because we previously demonstrated no improvement of fasting transferrin saturation over random samples to predict the C282Y genotype (6). Transferrin saturation also has considerable biological variability, which limits its value as a screening test (7). Many physicians will overestimate the probability of hemochromatosis because they may be unaware of the low specificity of transferrin saturation and ferritin values for hereditary hemochromatosis. A recent subanalysis from the HEIRS Study (8) demonstrated that only 10% to 12% of the participants with an elevated serum ferritin level (from 200µg/L to 1000 µg/L) had the C282Y genotype. A predictive
tool could focus the use of the hemochromatosis genetic test on participants with a high probability to avoid unnecessary testing costs and reduce the potential for adverse effects of genetic testing such as stigmatization and, less commonly, genetic discrimination (9). As with many screening tests, the utility of this tool is optimal at the low and high ends of the test value, with the middle values less informative. A patient with a low predicted probability could be evaluated first for other more common causes of an elevated serum ferritin level, and retested to determine whether the values change over time. A patient with a high probability should move directly to the genetic test. These equations are not intended to pre-empt the genetic test. They may be a useful clinical guide based on a large population-based sample, which reminds clinicians that there are many other causes of elevations in serum ferritin level and transferrin saturation that are not related to hemochromatosis.

**DISCLOSURES:** The authors have no financial disclosures or conflicts of interest to declare.

**REFERENCES**

Submit your manuscripts at http://www.hindawi.com